Table of Contents Table of Contents
Previous Page  133 / 154 Next Page
Information
Show Menu
Previous Page 133 / 154 Next Page
Page Background

A B S T R A C T S

S103

a significant correlation. Significant correlations for ECOG

versus TD and PFS (p=0.0047 and p<0.0001, respectively) and

for MNA versus PFS (p=0.0007) were observed in multivariate

analysis. Subgroup analysis excluding ECOG

2 patients no

longer showed significant correlations for ECOG; only MNA

and G8 (cut-off 12) were significantly associated with TD

(p=0.0481 and p=0.0165, respectively) and with PFS (p=0.0012

and p=0.0017, respectively), while G8 was correlated with

severe treatment toxicity (p=0.018).

Conclusion:

In this real-life study in older mCRC patients,

ECOG is a strong predictive marker for TD, PFS and severe

toxicity, mainly driven by a subpopulation of patients with

ECOG

2. MNA and G8 are predictive markers for TD and PFS

(and toxicity for G8) in the large group of patients with ECOG

1.

Disclosure of interest:

None declared

Keywords:

Bevacizumab, ECOG, Elderly, fTRST, geriatric

assessment

P113

CANCER SURVIVORSHIP AND AGING – IS IT SO DIFFERENT

FOR ELDERLY AND YOUNG?

M. Bernardo

1,

*, S. Ouakinin

2

, S. Eusébio

3

, L. Ribeiro

1

, O. Nunes

1

,

J. Silva

4

1

Hemato-oncology, Hospital CUF infante santo,

2

Psychiatry,

3

Psychology /Psychiatry, Fac Medicine Univ Lisboa,

4

Radiotherapy,

Hospital CUF descobertas, Lisboa, Portugal

Introduction:

Over the last decades the huge raise of cancer

survivors reflects significant improvement on diagnosis

and treatment of several cancers, as well as the best care of

multiple other diseases. The aging of population contributes

to significant numbers of older patients (on 2030 the number

of people who are older than 65 is expected to double as

compared to 2000). Cancer incidence globally raises with

age, and older patients have special and potentially unmet

needs, so it is important to understand if the comorbidities

are different in elderly and young patients

Objectives:

To compare the incidence and evaluate the

differences of comorbidities on a population of cancer

survivors (more than 10 years after diagnosis), stratifying

patients by age. Data on Quality of Life and distress will be

included on a subset of patients.

Methods:

Using a retrospective design, in a sample of

198 patients with more than 10 years of cancer survival, we

analysedmedical andpsychiatric comorbidities.Data obtained

from medical records included social and demographic data,

the characterization of tumor type and treatment approach,

the presence of second malignancies and comorbidities such

as diabetes, cardiovascular diseases, arterial hypertension,

lung, renal, hematologic, osteo-articular/ osteoporosis,

neurologic and psychiatric diseases, as well as obesity, pre

and pos-diagnosis and treatment of the malignancy. In a sub

sample of patients, distress levels and Quality of Life were

evaluated. Statistical analysis was performed using Statistical

Package for Social Sciences- SPSS V23.

Results:

In the whole sample age is less or equal to 50 years

in 21 subjects, between 51 and 69 years in 95 patients, and

70 years or more in 82 patients; 63,6% of them are females.

The most frequent diagnosis in patients aged 70 or more are

colorectal cancer (48,8%), breast cancer (23,2%), lymphoma

(6,1%) and lung cancer (4,9%). Using a non-parametric test

(Kruskal Wallis) to compare the distribution of comorbidities

in the 3 groups, we found significant differences between

groups for arterial hypertension (p<0.001) and for psychiatric

diseases (p<0.03). All comorbidities increased with age except

for psychiatric diseases, which decreases with age, and for

obesity, more frequent in patients between 51 and 69 years.

Conclusion:

Even though the retrospective nature of this

study, it shows few significant differences in medical profiles

in younger and older patients. We highlight the need to

consider particular health aspects in older populations, being

aware of their expected and increasing needs in support and

psychosocial dimensions.

References:

[1] Mao J, Armstrong K, Bowman M et al. Symptom

burden among cancer survivors: Impact of age and

comorbidityJABFM Sept-Oct 2007;40:5.434-43.

[2] Earle CC, Ganz PA. Cancer survivorship care: don’t let the

perfect be enemy of the good. J Clin Oncol. 2012;30:3764-68.

[3] Ligibel J. Lifestyle factors in cancer survivorship. J Clin

Oncol 2012;30:3697-704.

[4] Siegel R, DeSantis C,Virgo k, et al. Cancer treatment and sur-

vivorship statistics, 2012. CA Cancer J Clin 2012;62:220-41.

[5] Moslehi J. The cardiovascular perils of cancer survivorship.

N Engl J Med 2013;368:1055-56.

[6] Brennan ME, Gormally JF, Butow P, et al. Survivorship care

plans in cancer: a systematic review of care plan outcomes.

Br J Cancer 2014; 111:1899-1908.

[7] National Comprehensive Cancer Network. NCCN Clinical

Practice Guidelines in Oncology: Survivorship (version I.2015)

Disclosure of interest:

None declared

Keywords:

Cancer survivorship elderly comorbidities distress

P114

EVALUATION OF THE IMPACT OF COMPREHENSIVE

GERIATRIC ASSESSMENT (CGA) IN OLDER PATIENTS WITH

KIDNEY CANCER

M. Sanchez

1

, R. Boulahssass

2,

*, S. Gonfrier

1

, D. Saja

1

,

C. Rambaud

1

, J. M. Turpin

1

, F. Leborgne

1

, E. Clais

1

, E. Francois

3

,

O. Guerin

1

1

UCOG, CHU,

2

UCOG,

3

UCOG, Centre Antoine Lacassagne, Nice, France

Introduction:

In the future, life expectancy and incidence

of cancer will increase, and also incidence of kidney cancer

will increase in patients over 75 years old. The treatment of

kidney cancer is

surgery.We

observe in this population several

comorbidities which increase the risk of surgical morbidity

and could lead to only best supportive care.

Objectives:

The aim of this work is to determine the impact

of CGA in treatment decisions and also in guided geriatric

interventions.